Latest National Institute for Health and Clinical Excellence Stories
A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced today (18th January 2011).
HIGH WYCOMBE, England, July 9, 2010 /PRNewswire/ -- - In a draft appraisal the National Institute for Health and Clinical Excellence (NICE) has refused to recommend the first treatment shown to improve survival in childhood bone cancer (osteosarcoma) in more than 20 years(1,2) - Data shows Mepact(R) (mifamurtide) reduces the risk of death by almost one third when added to standard chemotherapy treatment, compared with chemotherapy alone(3) - Using...
SUNNYVALE, Calif., June 28 /PRNewswire/ -- BARRX Medical Inc., a world leader in products to treat pre-cancerous tissue in the esophagus, reported today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has published new guidelines approving the use of radiofrequency ablation for the eradication of dysplastic Barrett's esophagus. Barrett's esophagus is a precancerous condition that affects over 6.6 million people around the world and is caused by...
The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today.
RA'ANANA, Israel, May 17, 2010 /PRNewswire-FirstCall/ -- NICE Systems Ltd.
INDIANAPOLIS, April 1 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that its chemotherapy ALIMTAÂ® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).
PARIS, March 30, 2010 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY) announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document (ACD) for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation (AF). The NICE appraisal committee's preliminary recommendation is to endorse Multaq(R)...
Decisions about which drugs to abandon to fund new treatments recommended by the National Institute for Health and Clinical Excellence (NICE) are inconsistent and may be contributing to the postcode lottery â€“ one of the key issues that NICE was set up to tackle.
New research by health economists at the University of York has raised concerns over any move to broaden the range of costs and economic benefits considered in the analysis of new NHS treatments.
Research: Screening for postnatal depression in primary care: Cost effectiveness analysis.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.